newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio

  • Candel Therapeutics presented three posters at the SITC 41st Annual Meeting on Nov 4–8, 2026, detailing clinical & biomarker data for aglatimagene besadenovec in localized prostate cancer & non-squamous NSCLC, plus linoserpaturev in recurrent glioblastoma.
  • PrTK05 phase 2 data for aglatimagene in localized prostate cancer showed systemic CD8+ cytotoxic T-cell activation & transient biodistribution/shedding, supporting a planned BLA submission.
  • Aglatimagene phase 2a NSCLC data linked longitudinal immune changes & specific multi-omic features (including CD40L, NCR1, CXCL5, granzyme B) to survival beyond 24 months, reinforcing the rationale for the ongoing phase 3 AURORA trial.
  • Linoserpaturev phase 1b glioblastoma data demonstrated durable survival in a patient subset with persistent T-cell infiltration & exploratory immune changes to guide future development strategies.
  • In the PrTK05 prostate cancer trial, aglatimagene plus valacyclovir increased CD8+ T cells, activated proliferating T cells, & serum granzyme/perforin levels compared to standard-of-care alone.
  • PrTK05 results indicated transient aglatimagene vector DNA detection in blood with clearance in urine samples at weeks 16–18.
  • NSCLC trial results showed a median overall survival of 25.4 months, with 50% of patients alive at 24 months & 13% surviving beyond 50 months.
  • Glioblastoma Arm A+B data reported a median overall survival of 12.0 months (22% alive at 18 months), while Arm C data showed a median overall survival of 14.3 months.
  • Retrospective analysis of linoserpaturev patients who received subsequent bevacizumab did not show statistically significant overall survival improvement but suggested a hypothesis for prospective evaluation of treatment sequencing.
  • Aglatimagene is an investigational adenovirus delivering HSV-tk to induce immunogenic cell death & CD8+ T-cell responses, holding Fast Track & Regenerative Medicine Advanced Therapy designations for prostate cancer & NSCLC.
  • Linoserpaturev is a first-in-class replication-competent HSV-1 immunotherapy with Fast Track & Orphan Drug designations for recurrent high-grade glioma, currently in phase 1b trials.
Company
Candel Therapeutics, Inc
Keywords
Nasdaq:CADL, Candel Therapeutics, Inc